Clinical study of Shenyankangfu tablet combined with valsartan capsule on proteinuria in patients with stage IV diabetic nephropathy

Objective To investigate the therapeutic effects of Shenyankangfu tablet combined with valsartan capsule on proteinuria in patients with stage Ⅳ diabetic nephropathy and normal renal function.Methods 120 patients with stage Ⅳ diabetic nephropathy and normal renal function were randomly divided into two groups:valsartan group(n =60,valsartan 160 mg qd) and valsartan combined with Shenyankangfu tablets group (n =60,Shenyankangfu tablet 5 tablets tid combined with Valsartan 160 mg qd),and were treated for 16 weeks.Both groups were treated with the same basic diet control and routine treatment.After 16-week course of treatment,24 hours urinary protein,serum creatinine,blood glucose and blood lipids were determined and compared.Results Mter 16-week treatment,the total efficiency of the experiment group and the control group was 66.7％ and 46.7％ respectively,there was a significant difference between the two groups (P ＜ 0.05).The 24 hours urinary protein of both groups after treatment were significantly decreased,but in valsartan combined with Shenyankangfu tablets group,the 24 hours urinary protein decreased greatly [(1.77 ± 0.79) g vs.(2.29 ± 1.36) g,t =2.617,P ＜ 0.05].The levels of serum creatinine and blood glucose of both groups had no significant differences before and after treatment(P ＞ 0.05).Conclusion Shenyankangfu tablet combined with Valsartan capsule can decrease the urinary protein in patients with stage Ⅳ diabetic nephropathy,the therapeutic effect is better than valsartan alone. Key words: ShenyanKangfu tablet;  Valsartan capsule;  Diabetic nephropathy